Investigating the Safety of Fampridine in Patients with Different Stages of Multiple Sclerosis
Background: Fampridine is the only drug approved by the US Food and Drug Administration (FDA) for people with multiple sclerosis (MS) to improve their movement and has exhibited a clinically significant improvement in gait function in a subset of MS patients with Expanded Disability Status Scale (ES...
Saved in:
Main Authors: | Saeed Vaheb, Mahour Farzan, Alireza Afshari-Safavi, Narges Ebrahimi, Vahid Shaygannejad, Omid Mirmosayyeb |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
Series: | International Journal of Preventive Medicine |
Subjects: | |
Online Access: | https://journals.lww.com/10.4103/ijpvm.ijpvm_292_23 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
HPLC method development for fampridine using Analytical Quality by Design approach
by: Kovács Béla, et al.
Published: (2020-12-01) -
The prevalence of sexual dysfunction and erectile dysfunction in men with multiple sclerosis: A systematic review and meta-analysis
by: V. Shaygannejad, et al.
Published: (2025-01-01) -
Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis
by: Hui Chen
Published: (2025-01-01) -
Clinical Characteristics of Early-Onset and Late-Onset Multiple Sclerosis in Patients from Lithuania
by: Emilija Šlajūtė, et al.
Published: (2025-01-01) -
Optic neuritis and multiple sclerosis association
by: L. Matukynaitė, et al.
Published: (2020-09-01)